Association of Modified‐FOLFIRINOX‐Regimen‐Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population
Conclusion.Neoadjuvant chemotherapy such as the mFOLFIRINOX regimen can be recommended for Chinese patients with LAPC after dose modification. Patients with LAPC‐N who underwent surgery obtained significantly improved survival compared with patients in the observational LAPC‐S cohort, who did not undergo neoadjuvant therapy.
Source: The Oncologist - Category: Cancer & Oncology Authors: Xiang Li, Chengxiang Guo, Qinghai Li, Shumei Wei, Qi Zhang, Yiwen Chen, Yinan Shen, Tao Ma, Guogang Li, Shunliang Gao, Risheng Que, Jianying Lou, Risheng Yu, Ying Yuan, Qichun Wei, Pintong Huang, Tingbo Liang, Xueli Bai Tags: Chinese Edition, Clinical Trial Results, Gastrointestinal Cancer Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Chemotherapy | China Health | Clinical Trials | Gastroenterology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Study